A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Status:
NOT_YET_RECRUITING
Trial end date:
2030-03-31
Target enrollment:
Participant gender:
Summary
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability and preliminary efficacy of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.